Top Industry Players in Japan Anemia Market | Top Companies 2026

Japan Anemia Market Overview

According to 6Wresearch, the Japan anemia market is transitioning toward improved pharmacological treatments, particularly for the treatment of Renal Anemia. While traditional iron supplementation remains a standard treatment, the market has shifted to embrace innovative Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) inhibitors, which provide a more convenient oral alternative to conventional injectable Erythropoiesis-Stimulating Agents (ESAs).

Furthermore, with the intensification of screening for chronic kidney disease (CKD), domestic focus is expanding beyond simple nutrient replacement. There is an increasing demand for precision-dosage iron infusions and high-fidelity biotechnological treatments that cater to patients with complex comorbidities.

Competitive Landscape

The competitive landscape of the Japan anemia market is defined by a strategic synergy between domestic research-heavy firms and global biotech innovators. These companies compete to secure placement in the National Health Insurance (NHI) reimbursement system by focusing on clinical data that demonstrates both long-term safety and cost-effectiveness in compliance with Pharmaceuticals and Medical Devices Agency (PMDA) standards.

Below is a list of leading players operating in the Japan Anemia Market:

1. Takeda Pharmaceutical Company Limited

A major player in the Japanese market for anemia treatments, particularly in therapeutic innovation, Takeda manages an extensive portfolio of hematology products and provides critical supportive care for patients with chronic anemia.

2. Daiichi Sankyo Company, Limited

A key player, especially in the Japanese iron deficiency injectable market, resulting from their strong position in intravenous iron therapy and high-purity iron treatments for various blood-related disorders.

3. Kyowa Kirin Co., Ltd.

Prominent in the Japanese market for renal anemia and the manufacture of EPO products (Epoetin alfa), Kyowa Kirin is a dominant force known for its long-acting ESAs and innovative HIF-PH inhibitors.

4. Chugai Pharmaceutical Co., Ltd.

A significant contributor to anemia treatments, particularly within therapeutic areas linked to renal and chronic diseases, Chugai utilizes advanced antibody technology to develop treatments for rare and severe anemia.

5. Otsuka Holdings Co., Ltd.

A major domestic player with a broad portfolio of pharmaceutical products, active in hematology through its various subsidiaries that provide essential intravenous solutions and pharmaceutical care.

6. Akebia Therapeutics, Inc.

Known for developing innovative anemia treatments such as HIF-PH inhibitors (vadadustat) for patients with chronic kidney disease, Akebia operates in Japan through strategic commercial partnerships.

7. Pfizer Inc.

Provides a wide portfolio of products, including those for anemia associated with other blood disorders such as aplastic anemia, maintaining a significant clinical presence in Japan’s premium hospital sector.

8. Sanofi SA

Manufactures key iron therapy products, including Ferrlecit and Hemax, and is highly active in the treatment of rare blood disorders and specialized hematology within the Japanese market.

9. Bayer AG

A key provider of anemia drugs, including oral and intravenous options for chronic disease-related anemia, Bayer operates locally through Bayer Yakuhin, Ltd. to support the Japanese healthcare system.

10. Astellas Pharma Inc.

A primary player in the renal anemia segment, Astellas focuses on bringing global biotechnological advancements, such as oral HIF-PH inhibitors, to the Japanese domestic market.

11. Torii Pharmaceutical Co., Ltd.

A subsidiary of JT (Japan Tobacco), Torii specializes in renal and hemodialysis treatments, serving as a key supplier of iron-deficiency therapies for hospitalized patients.

12. Nippon Shinyaku Co., Ltd.

Specializes in intractable diseases and hematology, contributing to the market with niche products specifically designed for pediatric and rare anemia cases.

13. Zeria Pharmaceutical Co., Ltd.

A prominent name in the gastrointestinal and over-the-counter sectors, offering high-bioavailability iron supplements for self-medication and nutritional support.

14. Kyorin Pharmaceutical Co., Ltd.

Focuses on respiratory and renal health, providing essential supportive medications for anemia management within the Japanese clinical network.